Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines

8-K filing — Fulcrum Therapeutics, Inc. (FULC)

Filed: 2026-08-17 AccNo: 0001193125-26-353278 Size: 15 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Fulcrum Therapeutics And Slate Medicines Merge In All-Stock Deal; Combined Company To Operate As Slate Medicines

Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeuticsSlate’s lead product candidate, SLTE-1009, is a clinical stage, potentially

UPDATED: Fulcrum Therapeutics Launches Restructuring Plan Following Discontinuation Of Pociredir For Sickle Cell Disease, Cutting Workforce By 85% From 57 To 9 Employees And Recording ~$4.2M In Restructuring Charges